Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06899126 · ClinicalTrials.gov registry record · Phase 3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 686
- Enrollment target
- 20
- Study locations
NCT06899126: Recruiting Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Daiichi Sankyo.
NCT06899126 is a Phase 3 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 686 participants, roughly in line with the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06899126, a Phase 3 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 686 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.
Primary Outcome
PFS is defined as the time interval from the date of randomization to the date of radiographic disease progression or death due to any cause. Tumor response will be determined by BICR assessment of tumor scans using RECIST v1.1.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG Pemetrexed
- DRUG Chemotherapy
- DRUG Trastuzumab Deruxtecan
Study Locations (20)
California
- Orange Coast Memorial Medical Center Fountain Valley - Fountain Valley
- California Research Institute - Los Angeles
- Los Angeles Cancer Network (LACN) - Los Angeles
- Providence Medical Foundation - Santa Rosa
Florida
- Bay Pines VA Healthcare System - Bay Pines
- Holy Cross Hospital - Fort Lauderdale
- Mid-Florida Hematology & Oncology Centers, P.A. - Orange City
- BRCR Global Plantation - Plantation
Texas
- University of Texas M. D. Anderson Cancer Center - Houston
- Lumi Research - Kingwood
Other
- CINME - Centro De Investigaciones Metabolicas - Buenos Aires
- Instituto Argentino de Diagnostico y Tratamiento - Buenos Aires
Alaska
- Alaska Oncology & Hematology, LLC - Anchorage
Illinois
- Hope and Healing Cancer Services - Hinsdale
Montana
- Logan Health Research - Kalispell
New York
- Clinical Research Alliance - Westbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 686 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2032-07-05 |
| Phase | Phase 3 |
What NCT06899126 shows while recruiting
NCT06899126 is an interventional study that assigns participants to a tested intervention. The registered 686 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which pembrolizumab is the first listed.
NCT06899126 names 20 study sites across 12 states, led by California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06899126 about?
NCT06899126 is a clinical study titled "Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer". This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic n...
What is the current status of trial NCT06899126?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 686 participants. The study started on 2025-10-24. Estimated completion is 2032-07-05.
What conditions does trial NCT06899126 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06899126?
The interventions under investigation include: pembrolizumab (DRUG), Pemetrexed (DRUG), Chemotherapy (DRUG), Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT06899126?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06899126 being conducted?
This trial has 20 study locations across Alaska, California, Florida, Illinois, Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06899126's enrollment target sits among peer trials
686 45th of 454 higher than 410 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04333537 · 686 participants · Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- NCT06459180 · 686 participants · Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- NCT06618274 · 686 participants · NA
Effectiveness of Central Oncology Navigation and the Use of an ORN
- NCT05099770 · 685 participants · Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI